What's Happening?
A recent study has revealed that Resmetirom, a drug approved by the U.S. Food and Drug Administration (FDA) for treating metabolic dysfunction associated fatty liver disease (MAFLD), may also help prevent
and suppress liver cancer. Conducted by researchers from the University of Hong Kong, the study found that Resmetirom not only reduces liver fat but also slows tumor growth and lowers levels of the Midkine (MDK) protein, which is linked to cancer progression. The study highlights the potential of Resmetirom in reshaping the immune microenvironment and improving liver metabolism, suggesting its clinical value in future treatment strategies for liver cancer.
Why It's Important?
The findings of this study are significant as they offer a new potential treatment strategy for liver cancer, particularly for patients with fatty liver disease. Hepatocellular carcinoma (HCC) is a major global health concern, being the sixth most common cancer and the third leading cause of cancer-related deaths worldwide. The study's insights into the role of the MDK protein in cancer progression could lead to more effective treatments for patients who do not respond well to current therapies. By improving metabolic health and targeting cancer-promoting pathways, Resmetirom could provide a dual benefit in treating fatty liver disease and preventing liver cancer.
What's Next?
The research team plans to validate relevant biomarkers in larger patient cohorts and collaborate with clinicians to design clinical trials. These trials will explore the combination of Resmetirom with immunotherapy and targeted therapy, aiming to establish a prevention-oriented treatment approach for high-risk patients. This could potentially lead to new standards in the management of liver cancer, particularly for those with metabolic disorders.
